Rockwell Medical, Inc.

Rockwell Medical operates as a healthcare company developing hemodialysis products. The company manufactures and distributes various concentrates for dialysis providers worldwide. Products include CitraPure, Dri-Sate, RenalPure, and SteriLyte concentrates, as well as ancillary supplies. Hemodialysis concentrates sustain patients lives by removing toxins and balancing electrolytes. The company serves hemodialysis clinics. Rockwell Medical was formerly known as Rockwell Medical Technologies, Inc. before changing its name in 2012.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

1.1 USD

Potential

-100%

Strengths

Price to book ratio (1.12) is lower than the sector mean (733.70).
EV/EBITDA (10.25) is lower than the sector mean (51.86).
Price to free cash flow (11.42) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (10.17%) is significantly lower than the sector mean (14.71%).
EBITDA Margin (2.84%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	10.5
Price/Free Cash Flow'	11.6
ROIC	10.2%
Net Debt/EBITDA	100.0